Himadri Speciality Chemical Approves FY26 Audited Results & Recommends 80% Final Dividend
Himadri Speciality Chemical Ltd. approved its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company recommended a final dividend of Re. 0.80 per equity share (80%). Independent Directors Girish Paman Vanvari and Gopal Ajay Malpani were re-appointed for a second 5-year term.
The announcement includes the approval of financial results and a dividend recommendation, which are material events for shareholders. The planned incorporation of a foreign subsidiary and re-appointment of directors also contribute to the impact.
The company announced positive financial results and recommended a dividend, which are generally viewed favorably by investors. The re-appointment of independent directors and plans for a foreign subsidiary also indicate stability and growth.
Himadri Speciality Chemical Ltd. announced the outcome of its Board of Directors meeting held on 23 April 2026. The Board has approved the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended 31 March 2026.
The company also recommended a final dividend of Re. 0.80 per equity share (80%) for the financial year 2025-26, subject to shareholder approval.
In addition, the Board re-appointed M/s Ernst & Young, LLP as the Internal Auditor for FY 2026-27 and appointed Mr. Sambhu Banerjee as the Cost Auditor for the same period.
Furthermore, the Board approved the re-appointment of Mr. Girish Paman Vanvari and Mr. Gopal Ajay Malpani as Independent Directors for a second term of 5 years each, commencing from 22 June 2026 and 13 August 2026, respectively, subject to shareholder approval.
The company also disclosed the proposal to incorporate a wholly owned subsidiary in Guangzhou, China. The Board meeting commenced at 12:00 p.m. IST and concluded at 4:00 p.m. IST on 23 April 2026.
What to do with a filing like this
Himadri Speciality Chemical Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Himadri Speciality Chemical Limited. Read the original for the full detail.